IRB Approval for Anatabloc Human Clinical Study

Star Scientific, Inc., Glen Allen, VA, through its subsidiary, Rock Creek Pharmaceuticals, Inc., Gloucester, MA, has announced that it has received IRB approval of the first human clinical study of the safety and effects of nutritional supplementation with Anatabloc in individuals with Alzheimer’s disease. The study is a six-visit, double-blind, randomized, placebo-controlled, parallel-group trial to evaluate the safety, tolerability and potential effects of Anatabine dietary supplementation in subjects with mild to moderate Alzheimer’s disease. Secondary aims are to evaluate the effects of this specially formulated version of Anatabloc (patent pending) on amyloid beta, global outcome and functional measures of Alzheimer’s.